TibaRay has launched its Regulation CF campaign on Wefunder, opening the company to individual investors as it continues developing next generation accelerator technology designed to enable FLASH radiotherapy. The company's mission is to cure cancer in a FLASH by enabling radiation to be delivered hundreds of times faster than current systems. Research in recent years suggests that ultrafast radiation delivery, known as FLASH radiotherapy, may reduce damage to healthy tissue while maintaining tumor control.
Enabling this type of treatment requires fundamentally new accelerator technology, which TibaRay is developing. The company is a Stanford spinout built on decades of accelerator physics and medical physics research. To date, more than $27 million has been invested in the development of its technology, including over $14 million in non-dilutive federal research grants. TibaRay's intellectual property portfolio includes more than 20 issued and pending patents related to next generation radiotherapy systems.
TibaRay's proprietary Galactica linear accelerator has already been designed into Leo Cancer Care's upright radiotherapy system, marking the company's first commercial integration of its accelerator platform. The company is pursuing a phased commercialization strategy. In the near term, TibaRay generates revenue by commercializing its accelerator technology across medical and adjacent markets including imaging, security scanning, and non-destructive testing. The long term objective is deployment of the PHASER radiotherapy system designed to enable ultrafast treatment delivery.
The Wefunder campaign allows individual investors to participate in this next phase of development. Investors can review the full opportunity, including technology details, partnerships, and development plans on the TibaRay campaign page at https://wefunder.com/tibaray. This development represents a significant step toward making FLASH radiotherapy more accessible, potentially transforming cancer treatment by reducing side effects and improving patient outcomes. The technology could have far-reaching implications for the medical industry, offering a new approach to radiation therapy that balances efficacy with reduced harm to healthy tissues.
